At present, the main basis of PCa risk assessment includes clinical stage, pathological grade, and prostate-specific antigen (PSA) level, but the clinical evidence suggests that these are not enough to accurately evaluate the prognosis of PCa patients (5, 6). Here, KLK3 is linked to posterior cortical atrophy.